Algiers – Saidal Group, Algeria’s leading pharmaceutical company, is strengthening its international partnerships with a new collaboration aimed at advancing biotechnology and bolstering the nation’s healthcare sector. The group signed a Memorandum of Understanding (MOU) with Swiss-based Bioexpress Therapeutics on Sunday, January 11, 2026, marking a significant step in its strategic vision.
The agreement, formalized at Saidal Group’s headquarters, underscores the company’s commitment to global collaboration and its ambition to enhance its position in the pharmaceutical and biotechnology industries. The MOU was signed by Nabila Ben Yegzer Moularess, CEO of Saidal Group, and Gerrit Hagens, CEO, and Luc Alain Savoy, Chairman of Bioexpress Therapeutics.
The MOU establishes a strategic framework primarily focused on specialized training and the development of national competencies in biotechnology. This initiative aims to facilitate a gradual and organized transfer of technology, aligning with international standards in this vital sector. The ultimate goal is to create an environment conducive to the local production of biotechnological products.
This partnership is expected to significantly enhance Algeria’s domestic pharmaceutical capabilities, supporting the country’s efforts to achieve health sovereignty and reduce reliance on imports. The agreement reaffirms Saidal Group’s dedication to fostering innovation, valuing national expertise, integrating cutting-edge technologies, and expanding its network of partnerships with leading international players in pharmaceuticals and biotherapeutics. This collaborative approach is designed to serve the ongoing development of the national healthcare system and ensure access to advanced medical solutions for the Algerian population.
